Last reviewed · How we verify
Sodium Acetate C11 PET MRI
At a glance
| Generic name | Sodium Acetate C11 PET MRI |
|---|---|
| Also known as | C11 PET MRI |
| Sponsor | Michael C Roarke, MD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma (PHASE2)
- C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sodium Acetate C11 PET MRI CI brief — competitive landscape report
- Sodium Acetate C11 PET MRI updates RSS · CI watch RSS
- Michael C Roarke, MD portfolio CI